A study by Youjin Kim et al. on 467 NSCLC patients with EGFR mutations treated with first-line TKIs at Samsung Medical Center from 2014 to 2016 showed median PFS for Afatinib, Gefitinib, and Erlotinib were 19.1 months, 13.7 months, and 14.0 months, respectively [25]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.